1.
Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study.
Ha Ahnul, Kim Young Kook, Jeoung Jin Wook, Satyal Sanjeev, Kim Jaesoon, Kim Soojin et al.
Acta OphthalmolJul 202110 citationsRandomized Controlled Trial
Sovesudil, a new ROCK inhibitor, effectively lowered intraocular pressure in normal-tension glaucoma patients, with the 0.5% dose showing significant IOP reduction and good tolerability.